Johnson & Johnson and COVID-19: Vaccine Research and Development

iStock-1206774789+%281%29.jpg

In March 2020, the Johnson & Johnson Family of Companies and the Johnson & Johnson Foundation committed $50M for immediate COVID-19 response, primarily focused on supporting frontline health workers.

The company also announced that a lead vaccine candidate against COVID-19 has been selected to move into clinical trials by September 2020 at the latest, alongside news of a landmark $1B commitment to vaccine research and development between the Company and BARDA and plans for Johnson & Johnson to supply one billion vaccines worldwide for emergency pandemic use.

CorporateDaria DelnevoJohnson & Johnson